An anti-obesity drug has become the centre of a recent study conducted by the University of Cambridge.
The research looked at the effect of the drug sibutramine on brain responses.
Using functional magnetic resonance imaging, the scientists observed the responses of a number of obese volunteers when presented pictures of high and low-calorie food.
When the volunteers were given a placebo treatment, their brain activity increased in the areas associated with reward upon seeing a picture of high-calorie food.
However, after the sibutramine, brain responses were found to be reduced.
The images focused on the hypothalamus and the amygdale in the brain.
Professor Ed Bullmore, from the Department of Psychiatry at the University of Cambridge and director of the GlaxoSmithKline Clinical Unit in Cambridge, said: "Our results help us to understand more precisely how anti-obesity drugs work in the brain to change eating behaviour and hence, ultimately, to assist people in losing weight.
What's better? Private or NHS healthcare?